There were 101 press releases posted in the last 24 hours and 440,199 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image